• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For March 26, 2024

    3/26/24 4:47:27 AM ET
    $AACG
    $ABOS
    $AIM
    $APTO
    Other Consumer Services
    Real Estate
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AACG alert in real time by email

    Companies Reporting Before The Bell

    • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.

    • AIM ImmunoTech (AMEX:AIM) is estimated to report earnings for its fourth quarter.

    • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.38 per share on revenue of $1.52 billion.

    • GDS Holdings (NASDAQ:GDS) is likely to report quarterly loss at $0.33 per share on revenue of $357.63 million.

    • Bragg Gaming Group (NASDAQ:BRAG) is estimated to report quarterly loss at $0.01 per share on revenue of $37.82 million.

    • BioLine Rx (NASDAQ:BLRX) is expected to report earnings for its fourth quarter.

    • Zhihu (NYSE:ZH) is likely to report quarterly loss at $0.04 per share on revenue of $148.11 million.

    • DouYu Intl Hldgs (NASDAQ:DOYU) is estimated to report quarterly loss at $0.02 per share on revenue of $170.91 million.

    • Waterdrop (NYSE:WDH) is estimated to report quarterly earnings at $0.01 per share on revenue of $94.55 million.

    • Forza X1 (NASDAQ:FRZA) is likely to report earnings for its fourth quarter.

    • Acumen Pharmaceuticals (NASDAQ:ABOS) is likely to report earnings for its fourth quarter.

    • Twin Vee PowerCats (NASDAQ:VEEE) is likely to report earnings for its fourth quarter.

    • Delcath Systems (NASDAQ:DCTH) is expected to report quarterly loss at $0.51 per share on revenue of $540 thousand.

    • Volato Group (AMEX:SOAR) is estimated to report earnings for its fourth quarter.

    • Movado Group (NYSE:MOV) is likely to report quarterly earnings at $0.39 per share on revenue of $174.80 million.

    • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its fourth quarter.

    • McCormick & Co (NYSE:MKC) is expected to report quarterly earnings at $0.58 per share on revenue of $1.56 billion.

    • Kaspi.kz (NASDAQ:KSPI) is estimated to report earnings for its first quarter.

    • TD Synnex (NYSE:SNX) is likely to report quarterly earnings at $2.84 per share on revenue of $14.36 billion.

    Companies Reporting After The Bell

    • Sidus Space (NASDAQ:SIDU) is estimated to report earnings for its fourth quarter.

    • Marpai (NASDAQ:MRAI) is estimated to report earnings for its fourth quarter.

    • NovaBay Pharmaceuticals (AMEX:NBY) is likely to report quarterly loss at $0.30 per share on revenue of $3.40 million.

    • Aptose Biosciences (NASDAQ:APTO) is projected to report earnings for its fourth quarter.

    • Direct Digital Holdings (NASDAQ:DRCT) is likely to report quarterly earnings at $0.26 per share on revenue of $65.95 million.

    • US Energy (NASDAQ:USEG) is expected to report quarterly loss at $0.03 per share on revenue of $8.87 million.

    • X Financial (NYSE:XYF) is likely to report earnings for its fourth quarter.

    • Iridex (NASDAQ:IRIX) is likely to report quarterly loss at $0.05 per share on revenue of $14.90 million.

    • iPath Series B Carbon Exchange-Traded Notes (NYSE:GRN) is projected to report quarterly loss at $0.01 per share on revenue of $13.40 million.

    • Intrusion (NASDAQ:INTZ) is likely to report quarterly loss at $0.11 per share on revenue of $1.64 million.

    • BioAtla (NASDAQ:BCAB) is expected to report earnings for its fourth quarter.

    • GameStop (NYSE:GME) is likely to report quarterly earnings at $0.29 per share on revenue of $2.05 billion.

    • Forge Global Holdings (NYSE:FRGE) is likely to report quarterly loss at $0.10 per share on revenue of $19.57 million.

    • Biora Therapeutics (NASDAQ:BIOR) is expected to report earnings for its fourth quarter.

    • ProSomnus (NASDAQ:OSA) is expected to report quarterly loss at $0.31 per share on revenue of $7.37 million.

    • ATA Creativity Glb (NASDAQ:AACG) is likely to report earnings for its fourth quarter.

    • Noah Holdings (NYSE:NOAH) is estimated to report earnings for its fourth quarter.

    • PAVmed (NASDAQ:PAVM) is projected to report quarterly loss at $1.89 per share on revenue of $1.05 million.

    • AEye (NASDAQ:LIDR) is likely to report quarterly loss at $1.20 per share on revenue of $100 thousand.

    • Velo3D (NYSE:VLD) is likely to report quarterly loss at $0.08 per share on revenue of $19.50 million.

    • Progress Software (NASDAQ:PRGS) is expected to report quarterly earnings at $1.14 per share on revenue of $181.91 million.

    • WidePoint (AMEX:WYY) is estimated to report earnings for its fourth quarter.

    • LuxUrban Hotels (NASDAQ:LUXH) is expected to report quarterly earnings at $0.09 per share on revenue of $34.20 million.

    • Oxbridge Re Holdings (NASDAQ:OXBR) is expected to report earnings for its fourth quarter.

    • Concentrix (NASDAQ:CNXC) is estimated to report quarterly earnings at $2.58 per share on revenue of $2.38 billion.

    • Ouster (NYSE:OUST) is likely to report quarterly loss at $0.83 per share on revenue of $24.06 million.

    • Ncino (NASDAQ:NCNO) is expected to report quarterly earnings at $0.12 per share on revenue of $124.62 million.

    • PaySign (NASDAQ:PAYS) is projected to report quarterly earnings at $0.02 per share on revenue of $12.62 million.

    • Ryvyl (NASDAQ:RVYL) is estimated to report quarterly loss at $0.40 per share on revenue of $18.00 million.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AACG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AACG
    $ABOS
    $AIM
    $APTO

    CompanyDatePrice TargetRatingAnalyst
    Joint Stock Company Kaspi.kz
    $KSPI
    2/2/2026$87.00Positive → Neutral
    Susquehanna
    BioAtla Inc.
    $BCAB
    1/13/2026$4.00Buy
    Rodman & Renshaw
    TD SYNNEX Corporation
    $SNX
    1/13/2026$180.00Buy
    Goldman
    Movado Group Inc.
    $MOV
    1/7/2026$30.00Outperform
    Northland Capital
    nCino Inc.
    $NCNO
    12/17/2025Neutral
    BTIG Research
    McCormick & Company Incorporated
    $MKC
    12/15/2025$75.00Hold → Buy
    Deutsche Bank
    Forge Global Holdings Inc.
    $FRGE
    12/12/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Elbit Systems Ltd.
    $ESLT
    12/11/2025Equal-Weight
    Morgan Stanley
    More analyst ratings

    $AACG
    $ABOS
    $AIM
    $APTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    1/23/24 4:36:46 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $AACG
    $ABOS
    $AIM
    $APTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

    Live video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview and business outlook and will focus on AIM's strategic emphasis on pancreatic cancer. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:40 PM ESTPresenter: Thomas K. Equels, MS JD, Chief Executive Officer Registration Link: Here S

    2/6/26 8:55:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Destinations International Names Orange 142's Cassandra Razzi to Social Impact Committee

    Appointment builds on Orange 142's work helping destination organizations drive visitation, revenue, and community impact AUSTIN, Texas, Feb. 5, 2026 /PRNewswire/ -- Orange 142,  LLC ("Orange 142"), a leading digital marketing agency and a division of Direct Digital Holdings (NASDAQ:DRCT), today announced that Cassandra Razzi, Senior Manager of Business Development, has been named to the 2026 Social Impact Committee of Destinations International (DI), the world's largest association for destination organizations and tourism professionals. The appointment reflects Orange 142's ongoing work with destination marketing organizations (DMOs) to expand reach, drive revenue, and support responsible

    2/5/26 9:00:00 AM ET
    $DRCT
    Advertising
    Consumer Discretionary

    AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

    OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the "DURIPANC" study) (see: ClinicalTrials.gov NCT05927142). This is a follow-up Phase 2 to a 57-subject early access program ("EAP") of Ampligen as a monotherapy in late-stage pancreatic cancer, where Ampligen was associated with median survival of 19.7 mo

    2/5/26 8:40:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AACG
    $ABOS
    $AIM
    $APTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $3,450 worth of shares (2,500 units at $1.38), increasing direct ownership by 2% to 115,190 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/3/26 6:21:19 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    President and CEO Caldwell Christopher A bought $37,070 worth of shares (1,000 units at $37.07), increasing direct ownership by 0.28% to 362,075 units (SEC Form 4)

    4 - Concentrix Corp (0001803599) (Issuer)

    2/2/26 4:32:18 PM ET
    $CNXC
    Computer Software: Prepackaged Software
    Technology

    Chief Financial Officer Dizon Romeo R bought $1,588 worth of shares (1,101 units at $1.44), increasing direct ownership by 0.99% to 112,690 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    1/29/26 3:58:25 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AACG
    $ABOS
    $AIM
    $APTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chemerow David I. was granted 2,800 shares (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    2/6/26 5:03:20 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP of Accounting Sellers Jeanette sold $64,690 worth of shares (3,512 units at $18.42), decreasing direct ownership by 8% to 43,219 units (SEC Form 4)

    4 - nCino, Inc. (0001902733) (Issuer)

    2/5/26 5:40:21 PM ET
    $NCNO
    Computer Software: Prepackaged Software
    Technology

    Chief Lgl. & Admin Ofc., Sec Rieger April sold $150,913 worth of shares (8,078 units at $18.68), decreasing direct ownership by 4% to 221,696 units (SEC Form 4)

    4 - nCino, Inc. (0001902733) (Issuer)

    2/5/26 5:39:12 PM ET
    $NCNO
    Computer Software: Prepackaged Software
    Technology

    $AACG
    $ABOS
    $AIM
    $APTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kaspi.kz downgraded by Susquehanna with a new price target

    Susquehanna downgraded Kaspi.kz from Positive to Neutral and set a new price target of $87.00

    2/2/26 6:49:58 AM ET
    $KSPI

    Rodman & Renshaw initiated coverage on BioAtla with a new price target

    Rodman & Renshaw initiated coverage of BioAtla with a rating of Buy and set a new price target of $4.00

    1/13/26 3:22:40 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Goldman resumed coverage on TD Synnex with a new price target

    Goldman resumed coverage of TD Synnex with a rating of Buy and set a new price target of $180.00

    1/13/26 9:18:14 AM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    $AACG
    $ABOS
    $AIM
    $APTO
    SEC Filings

    View All

    BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure

    8-K - BioAtla, Inc. (0001826892) (Filer)

    2/6/26 5:02:26 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by GDS Holdings Limited

    6-K - GDS Holdings Ltd (0001526125) (Filer)

    2/6/26 8:43:35 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    SEC Form 6-K filed by GDS Holdings Limited

    6-K - GDS Holdings Ltd (0001526125) (Filer)

    2/6/26 8:03:49 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    $AACG
    $ABOS
    $AIM
    $APTO
    Leadership Updates

    Live Leadership Updates

    View All

    Hyve Solutions Announces Leadership Transition

    Jerry Kagele Named President; Steve Ichinaga Transitions to Advisory Role After 15 Years Leading Hyperscale Infrastructure Pioneer Hyve Solutions Corporation, a wholly owned subsidiary of TD SYNNEX Corporation (NYSE:SNX) and a leader in the design to worldwide deployment of hyperscale digital infrastructures, today announced that Jerry Kagele has been named President of Hyve Solutions. Kagele succeeds Steve Ichinaga, who is transitioning to an advisory role after four decades of service at TD SYNNEX, including the last 15 years as the founding executive of Hyve Solutions. This planned leadership transition positions the company for continued growth and seamless operational continuity. I

    1/27/26 5:00:00 PM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    McCormick Appoints Gavin Hattersley and Rick Dierker to Board of Directors

    HUNT VALLEY, Md., Jan. 21, 2026 /PRNewswire/ -- McCormick & Company, Incorporated (NYSE:MKC), a global leader in flavor, today announced that Gavin Hattersley, retired President and Chief Executive Officer of Molson Coors Beverage Company, and Rick Dierker, President and Chief Executive Officer of Church & Dwight Co., Inc., have been appointed to McCormick's Board of Directors effective February 1, 2026. Mr. Hattersley brings more than 35 years of leadership experience spanning the global consumer packaged goods and beverage industries. Most recently, he served as President an

    1/21/26 4:15:00 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    $AACG
    $ABOS
    $AIM
    $APTO
    Financials

    Live finance-specific insights

    View All

    Kaspi.kz to Announce 4th Quarter & Full-Year 2025 Financial Results on 2nd March

    ALMATY, Kazakhstan, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Kaspi.kz (KSPI US) will report its financial results for the quarter and year ending December 31st, 2025, on Monday, 2nd March, 2026. On that day, management will hold a conference call and webcast at 8.00am EST to review and discuss the company's results for the period. 4th Quarter & full-year 2025 Financial Results Conference Call Monday, 2nd March, 2026 To pre-register for this call, please go to the following link:Register Now You will receive your access details via email. About Kaspi.kz Kaspi.kz's mission is to improve people's lives by developing innovative mobile products and services. To deliver upon this we operate a u

    2/5/26 6:50:00 AM ET
    $KSPI

    GDS Announces Private Placement of US$300 Million convertible preferred shares to A Chinese Institutional Investor

    SHANGHAI, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- GDS Holdings Limited ("GDS Holdings", "GDS" or the "Company") (NASDAQ:GDS, HKEX: 9698)), a leading developer and operator of high-performance data centers in China, today announced a private placement of US$300 million of Series B convertible preferred shares (the "convertible preferred shares") to Huatai Capital Investment Limited, a Chinese institutional investor (the "Private Placement"). GDS will use the proceeds from the private placement to fund expansion of its data center capacity and for general corporate purposes. The convertible preferred shares include the following key terms: During the first six years from their issuance da

    1/30/26 8:40:00 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    Ouster Announces Date for Fourth Quarter 2025 Earnings Call

    Company to Report Q4 2025 Results on March 2, 2026 Ouster, Inc. (NASDAQ:OUST) ("Ouster" or the "Company"), a global leader in high-performance lidar sensors and intelligent software solutions that bring Physical AI to life across the automotive, industrial, robotics, and smart infrastructure sectors, announced today that it will report its financial results for the quarter ended December 31, 2025 after the market closes on Monday, March 2, 2026 and host a conference call that day at 5:00 p.m. ET to discuss its results. Registration for the webcast can be completed by visiting the following website prior to, or on the day of, the conference call: https://edge.media-server.com/mmc/p/yvxar

    1/26/26 6:00:00 AM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    $AACG
    $ABOS
    $AIM
    $APTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by nCino Inc.

    SC 13D/A - nCino, Inc. (0001902733) (Subject)

    12/12/24 6:29:06 PM ET
    $NCNO
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care